Acceptability of the Dapivirine Vaginal Ring in Postmenopausal US Women.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 9607225 Publication Model: Print Cited Medium: Internet ISSN: 1557-7449 (Electronic) Linking ISSN: 10872914 NLM ISO Abbreviation: AIDS Patient Care STDS Subsets: MEDLINE
    • Publication Information:
      Original Publication: Larchmont, NY : Mary Ann Liebert, Inc., c1996-
    • Subject Terms:
      Anti-HIV Agents*/therapeutic use ; Contraceptive Devices, Female* ; HIV Infections*/drug therapy ; HIV Infections*/epidemiology ; HIV Infections*/prevention & control; Female ; Humans ; Male ; Postmenopause ; Pyrimidines
    • Abstract:
      For women in the United States who remain sexually active beyond child-bearing years, susceptibility to HIV infection remains, yet condom use is low. We assessed acceptability of the dapivirine vaginal ring (ring) among 96 postmenopausal US women enrolled in a placebo-controlled multisite phase II trial of the ring, using questionnaires and in-depth interviews. Three quarters of women reported "perfect" adherence (ring never out) over the 3-month trial period. At study exit, the ring was found to be very easy to use by 72%, very comfortable to wear by 65%, and 4% reported it ever interfered with their daily activities. The most common worries among participants at preinitiation had decreased significantly at study exit (e.g., worries about inserting the ring declined from 46% to 6%, discomfort during daily activities from 53% to 3%, ring not staying in place from 48% to 14%, all p  < 0.0001). Despite some couples feeling the ring during sex, the ring was perceived as more suitable than condoms for prevention because it was not burdensome to use, did not interfere with erection, and provided (for some) additional vaginal lubrication. The ring is a promising, highly acceptable HIV prevention method that is suitable to the lives of postmenopausal women and their male partners and can provide them with an additional prevention choice. Clinical Trials Registration: NCT02010593.
    • References:
      Health Qual Life Outcomes. 2004 Sep 02;2:45. (PMID: 15345062)
      J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):197-201. (PMID: 31809308)
      AIDS Behav. 2020 Mar;24(3):866-880. (PMID: 31111297)
      JAMA. 2018 Mar 27;319(12):1261-1268. (PMID: 29584848)
      Mucosal Immunol. 2011 Nov;4(6):671-81. (PMID: 21881573)
      N Engl J Med. 2016 Dec;375(22):2133-2143. (PMID: 27959766)
      J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):221-8. (PMID: 22083068)
      Curr Opin HIV AIDS. 2012 Nov;7(6):534-41. (PMID: 23032737)
      AIDS Res Hum Retroviruses. 2017 Aug;33(8):807-819. (PMID: 28398069)
      Am J Public Health. 2012 Aug;102(8):1516-26. (PMID: 22698038)
      Clin Infect Dis. 2019 Mar 19;68(7):1144-1151. (PMID: 30289485)
      AIDS Behav. 2021 Sep;25(9):2801-2814. (PMID: 34117592)
      J Int AIDS Soc. 2019 Jul;22 Suppl 4:e25298. (PMID: 31328444)
      Adv Ther. 2020 May;37(5):1778-1811. (PMID: 32232664)
      J Acquir Immune Defic Syndr. 2019 Jul 1;81(3):304-310. (PMID: 30844995)
      Clin Infect Dis. 2020 Jul 27;71(3):583-585. (PMID: 31509603)
      N Engl J Med. 2016 Dec;375(22):2121-2132. (PMID: 26900902)
      AIDS Behav. 2018 Feb;22(2):437-446. (PMID: 29151197)
      PLoS One. 2018 Nov 29;13(11):e0207005. (PMID: 30496302)
      AIDS Behav. 2021 Jun;25(6):1890-1900. (PMID: 33389318)
      J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):606-608. (PMID: 27846073)
      PLoS One. 2019 Nov 8;14(11):e0224898. (PMID: 31703094)
      AIDS Care. 2017 Jul;29(7):866-869. (PMID: 28147704)
      J Int AIDS Soc. 2020 Nov;23(11):e25634. (PMID: 33206462)
      Eur J Contracept Reprod Health Care. 2012 Oct;17(5):340-50. (PMID: 22834648)
      BMJ. 1992 Mar 28;304(6830):809-13. (PMID: 1392708)
      Lancet HIV. 2021 Feb;8(2):e77-e86. (PMID: 33539761)
      Clin Infect Dis. 2021 Feb 1;72(3):379-385. (PMID: 33527117)
      AIDS Behav. 2016 Nov;20(11):2644-2653. (PMID: 26837628)
      Sex Transm Dis. 2010 Jun;37(6):361-4. (PMID: 20514687)
      Lancet HIV. 2021 Feb;8(2):e87-e95. (PMID: 33539762)
      Contraception. 2022 Feb;106:16-33. (PMID: 34644609)
      AIDS. 2016 Jul 31;30(12):1973-83. (PMID: 27149090)
      PLoS One. 2016 Mar 10;11(3):e0147743. (PMID: 26963505)
      AIDS Patient Care STDS. 2020 Mar;34(3):132-146. (PMID: 32202930)
    • Grant Information:
      P30 MH062246 United States MH NIMH NIH HHS; UM1 AI069494 United States AI NIAID NIH HHS
    • Contributed Indexing:
      Keywords: acceptability and preference; dapivirine; intravaginal ring; microbicides; postmenopausal; pre-exposure prophylaxis
    • Molecular Sequence:
      ClinicalTrials.gov NCT02010593
    • Accession Number:
      0 (Anti-HIV Agents)
      0 (Pyrimidines)
      TCN4MG2VXS (Dapivirine)
    • Publication Date:
      Date Created: 20220315 Date Completed: 20220405 Latest Revision: 20220924
    • Publication Date:
      20240105
    • Accession Number:
      PMC8971982
    • Accession Number:
      10.1089/apc.2022.0002
    • Accession Number:
      35289688